Abstract Description
Institution: Aarhus University - Danmark
Background:
Diabetic polyneuropathy (DPN) is a common complication of type 2 diabetes (T2D). Up to 50 % ofpatients with DPN suffer from neuropathic pain (P-DPN). The relationship between severity insensory symptoms, signs and the development of pain in DPN is relatively unstudied.Neuroinflammation is thought to contribute to the development of DPN and P-DPN. There is a lack ofprospective studies on DPN and P-DPN.
Methods:
Originally, 389 patients with newly diagnosed T2D and a likelihood of polyneuropathy as assessedby questionnaire and 97 healthy controls were recruited to establish the diagnosis of DPN. Allparticipants from the baseline study will be invited for a 5 year follow up examination
Results:
As of November 1st 2022 303 participants have been invited and 149 participants (follow-up rate: 49 %) have agreed to a follow-up visit. Of these, 119 participants (91 diabetes patients + 28controls) have completed the examinations. Mean follow-up time was 4.6 (SD 0.7) years and mean diabetes duration was 6.1 (SD 2.6) years and 10.8 (SE 2.6) years at baseline and follow-up, respectively. 20.9 % had painful DPN at baseline, which decreased slightly to 19.8 % at follow-up.7.7 % had developed neuropathic pain while 8.8 had experienced remission of pain. Data onsymptoms and diagnostic changes are currently being processed and the study is ongoing
Conclusions:
With the lack of prospective studies in DPN, this study will provide a unique insight into the naturalhistory of DPN and P-DPN.
Diabetic polyneuropathy (DPN) is a common complication of type 2 diabetes (T2D). Up to 50 % ofpatients with DPN suffer from neuropathic pain (P-DPN). The relationship between severity insensory symptoms, signs and the development of pain in DPN is relatively unstudied.Neuroinflammation is thought to contribute to the development of DPN and P-DPN. There is a lack ofprospective studies on DPN and P-DPN.
Methods:
Originally, 389 patients with newly diagnosed T2D and a likelihood of polyneuropathy as assessedby questionnaire and 97 healthy controls were recruited to establish the diagnosis of DPN. Allparticipants from the baseline study will be invited for a 5 year follow up examination
Results:
As of November 1st 2022 303 participants have been invited and 149 participants (follow-up rate: 49 %) have agreed to a follow-up visit. Of these, 119 participants (91 diabetes patients + 28controls) have completed the examinations. Mean follow-up time was 4.6 (SD 0.7) years and mean diabetes duration was 6.1 (SD 2.6) years and 10.8 (SE 2.6) years at baseline and follow-up, respectively. 20.9 % had painful DPN at baseline, which decreased slightly to 19.8 % at follow-up.7.7 % had developed neuropathic pain while 8.8 had experienced remission of pain. Data onsymptoms and diagnostic changes are currently being processed and the study is ongoing
Conclusions:
With the lack of prospective studies in DPN, this study will provide a unique insight into the naturalhistory of DPN and P-DPN.
Presenters
Authors
Authors
MD, PhD-student Peter Kolind Brask-Thomsen - Danish Pain Research Center , Msc, PhD, Associate Professor Páll Karlsson - Danish Pain Research Center , MD, DrMedSc, Professor Troels Staehelin Jensen - Danish Pain Research Center , MD, PhD, Professor Hatice Tankisi - Department of Neurophysiology, Aarhus University Hospital , Md, DrMedSc, Professor Nanna Brix Finnerup - Danish Pain Research Center, Aarhus University and Department of Neurology, Aarhus University Hospital , MD, PhD, Associate Professor Sandra Sif Gylfadottir - Danish Pain Research Center, Aarhus University and Department of Neurology, Aarhus University Hospital
